Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis

Aug 04 2017

• By Mandy Jackson

Eye

Related Content

Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?

Apr 19 2017

Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?

Jul 26 2017

Full Circle: Allergan's Revenue Growth Fuels Reinvestment In Sales, R&D

May 10 2017

Allergan buys chin fat firm Kythera for $2.1bn

Jun 18 2015

‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Oct 28 2016

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva

Jul 27 2015

Naurex presents 'compelling' data for depression drug GLYX-13

Dec 11 2014

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Feb 04 2017

VENUS II Paves Way For Allergan's Ulipristal NDA In Uterine Fibroids

Jan 18 2017

Related Companies

Allergan plc

Takeda Pharmaceutical Co. Ltd.

Merck & Co., Inc.

Amgen, Inc.

Novartis AG

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Additional Topics

Sales & Earnings Business Strategies Commercial Aesthetics Ophthalmic BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window